Showing 3971-3980 of 5646 results for "".
- Genentech: New Vabysmo Data Suggest Greater Retinal Drying vs. Aflibercept in Wet AMD and DMEhttps://modernod.com/news/genentech-new-vabysmo-data-suggest-greater-retinal-drying-vs-aflibercept-in-wet-amd-and-dme/2481564/Genentech announced that post-hoc data indicate treatment with Vabysmo (faricimab-svoa) led to greater and faster drying of retinal fluid with fewer injections compared to aflibercept in wet age-related macular degeneration (AMD). In diabetic macular edema (DME), post-hoc data suggest V
- Zeiss Receives FDA Approval of the CT Lucia 621P Monofocal IOLhttps://modernod.com/news/zeiss-receives-fda-approval-of-the-ct-lucia-621p-monofocal-iol/2481561/Zeiss announced that the FDA has approved the CT Lucia 621P monofocal IOL, an aspheric, monofocal, single-piece C-loop IOL. The IOL features the patented Zeiss Optic (ZO) Asphericity Concept, which is designed to compensate for a wide range of spherical aberrations and at
- Apellis Presents Phase 3 Functional Analyses of Syfovre for Geographic Atrophyhttps://modernod.com/news/apellis-presents-phase-3-functional-analyses-of-syfovre-for-geographic-atrophy/2481553/Apellis Pharmaceuticals announced post hoc analyses from the 24-month, phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analyses were reported during oral presenta
- SightGlass Vision: Research Reinforces Myopia Control Efficacy and Safety of Diffusion Optics Technology Spectacle Lenseshttps://modernod.com/news/sightglass-vision-research-reinforces-myopia-control-efficacy-and-safety-of-diffusion-optics-technology-spectacle-lenses/2481552/SightGlass Vision announced positive outcomes of multiple studies designed to evaluate the performance of its Diffusion Optics Technology spectacle lenses, which are designed to slow the progression of myopia in children. All are being presented this week at the 2023 ARVO Annual Me
- CooperVision: Study Links Individual OSDI Responses to Clinical Measures, Spotlighting Possible Treatmenthttps://modernod.com/news/coopervision-study-links-individual-osdi-responses-to-clinical-measures-spotlighting-possible-treatment/2481551/Preliminary results from a new study indicate that individual question responses within the widely-used Ocular Surface Disease Index (OSDI) symptom questionnaire can be correlated to specific clinical measures, providing eye care professionals better insight on treatment pathways. The Cooper
- CooperVision Seeks Proposals for 2023 Science and Technology Awardshttps://modernod.com/news/coopervision-seeks-proposals-for-2023-science-and-technology-awards/2481549/CooperVision announced it is now accepting submissions for its 2023 Science and Technology Awards program. The program enables researchers around the world to explore new dimensions in vision care, with the goal of translating innovative ideas into practical solutions. Each year, Cooper
- Ocugen to Present on Modifier Gene Therapy Platform at ARVO 2023https://modernod.com/news/ocugen-to-present-on-modifier-gene-therapy-platform-at-arvo-2023/2481547/Ocugen announced that the company will present on its modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis; OCU410 for the treatment dry age-related macular degeneration (dry AMD); OCU410ST for the treatment of St
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-3-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481543/Visus Therapeutics reported positive topline results from its phase 3 pivotal BRIO-I trial. BRIO-I met the prespecified primary study endpoints agreed upon with the FDA and EMA/MHRA, demonstrating contribution of elements for the once-daily, fixed-dose combination, Brimochol PF, over both ac
- Iridex Announces US Launch of Next Generation PASCAL Laser with MicroPulsehttps://modernod.com/news/iridex-launches-next-gen-pascal-laser-with-micropulse-in-us/2481542/Iridex announced the full market launch of the next generation Iridex PASCAL platform. First offered in limited release in late 2022, the PASCAL is designed to provide an advanced technology package combining fast and precise pattern scanning capabilities, Endpoint Management Techn
- Aviceda Announces FDA Clearance of the IND Application Enabling Phase 2 Trials for GA Drug Candidatehttps://modernod.com/news/aviceda-announces-fda-clearance-of-the-ind-application-enabling-phase-2-trials-for-geographic-atrophy-drug-candidate/2481529/Aviceda Therapeutics announced that the FDA has cleared the IND for AVD-104, enabling the company to proceed with initiating phase 2 clinical trials of its lead intravitreal ocular asset for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Pha